Document is current
Any future updates will be listed below
-
Authors
Chen, Nan
Matossian, Margarite
Saha, Poornima
Rampurwala, Murtuza
Kamaraju, Salaija
Hahn, Olwen
Howard, Frederick M.
Fleming, Gini F.
Freeman, Jincong Q.
Karrison, Theodore
Conzen, Suzanne
Nanda, Rita
Stringer-Reasor, Erica M.
-
Funding
Funding for this research was provided by:
National Cancer Institute (K08CA283261, K08CA283261)
National Institutes of Health (T32GM007019)
National Institute on Aging (T32AG000243)
- License Information
-
More Information
Article History
Received: 3 September 2024
Accepted: 24 January 2025
First Online: 10 February 2025
Declarations
:
: NC has disclosed consultant funding from Seagen, Stemline, Guardant Health and institutional funding from Eli Lilly. MM has no disclosures. PS has no disclosures. MR has no disclosures. SK has no disclosures. OH has no disclosures. FMH has disclosed consultant funding from Novartis. GF has disclosed institutional funding from Roche, Iovance, Sermonix, Compugen, AstraZeneca, Astellas, K group beta, Pfizer, Artios, Blueprint, and Duality Bio. JQF has no disclosures. TK has no disclosures. SC has patents issued to the University of Chicago for methods and compositions related to glucocorticoid receptor antagonists and breast cancer. RN disclosed consulting funding from AstraZeneca, BeyondSpring, Fujifilm, GE, Gilead, Infinity, iTeos, Merck, OBI Pharma, Oncosec, Sanofi, Seattle Genetics and research funding from Arvinas, AstraZeneca, BMS, Corcept Therapeutics, Genentech/Roche, Gilead, GSK, Merck, Novartis, OBI Pharma, OncoSec,Pfizer, Relay, Seagen, Sun Pharma, Taiho. ES has disclosed consultant funding from Seagen, Novartis, Merck, Eli Lilly, AstraZeneca, Gilead and institutional funding from Eli Lilly, Pfizer, Novartis, Tesaro, GSK, Merck, and Corcept Therapeutics.
